Adagene Inc.
アダジェン株式会社別名天演药业別名
§01
基本情報
- 所在地
- 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, 215123, China
- 社長
- Peter Luo
- 従業員数(単独)
- 従業員数(連結)
- 開始日
- 終了日
§02
サイト
§03
事業内容
antibody discoveryantibody engineeringprecision-guided antibody-drug conjugate developmenttransformative antibody designAntibody Gene TherapyCancer ImmunotherapyPrecision ImmunotherapyAntibody DiscoveryAntibody Engineering R&DAntibody-Drug Conjugate (ADC) R&Danti-CD47 antibodyCD20xCD3 bispecific T-cell engagerSAFEbody technologyPOWERbody technologyantibody-based cancer immunotherapiesAI-driven antibody discovery and development platformbispecific T-cell engager (TCE) developmentantibody-drug conjugate (ADC) developmentNEObody™ technologySAFEbody™ technologyPOWERbody™ technologydevelopment of anti-CD137 agonist antibody ADG106 for treatment of advanced solid tumours and non-Hoclinical trials of ADG106 in combination with anti-PD-1 antibody Nivolumab for advanced non-small ceantibody-based immunotherapiesclinical-stage oncology candidatesanti-CTLA-4 monoclonal antibodiescombination trials with pembrolizumabphase 1 monotherapy trialsphase 1 combination trialspreclinical programs towards INDclinical development of ADG106biopharmaceutical developmentcell line and upstream process developmentclinical-stage biopharmaceutical companynovel antibody-based cancer immunotherapiescomputational biology and artificial intelligence antibody designDPL platformNEObody technologyclinical-stage biopharmaceutical development of antibody-based immunotherapiesimmuno-oncology treatmentsanti-CTLA-4 monoclonal antibody (mAb) product candidatesclinical-stage biopharmaceutical developmentAI-driven drug discovery platformsADG116ADG126
antibody engineeringprecision-guided antibody-drug conjugate developmenttransformative antibody designAntibody Gene TherapyCancer ImmunotherapyPrecision ImmunotherapyAntibody DiscoveryAntibody Engineering R&DAntibody-Drug Conjugate (ADC) R&Danti-CD47 antibodyCD20xCD3 bispecific T-cell engagerSAFEbody technologyPOWERbody technologyantibody-based cancer immunotherapiesAI-driven antibody discovery and development platformbispecific T-cell engager (TCE) developmentantibody-drug conjugate (ADC) developmentNEObody™ technologySAFEbody™ technologyPOWERbody™ technologydevelopment of anti-CD137 agonist antibody ADG106 for treatment of advanced solid tumours and non-Hoclinical trials of ADG106 in combination with anti-PD-1 antibody Nivolumab for advanced non-small ceantibody-based immunotherapiesclinical-stage oncology candidatesanti-CTLA-4 monoclonal antibodiescombination trials with pembrolizumabphase 1 monotherapy trialsphase 1 combination trialspreclinical programs towards INDclinical development of ADG106biopharmaceutical developmentcell line and upstream process developmentclinical-stage biopharmaceutical companynovel antibody-based cancer immunotherapiescomputational biology and artificial intelligence antibody designDPL platformNEObody technologyclinical-stage biopharmaceutical development of antibody-based immunotherapiesimmuno-oncology treatmentsanti-CTLA-4 monoclonal antibody (mAb) product candidatesclinical-stage biopharmaceutical developmentAI-driven drug discovery platformsADG116ADG126
§04
関連会社
| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
|
Merck
|
||||||||
|
Bristol-Myers Squibb
|
||||||||
|
Dragon Boat Pharmaceuticals
|
||||||||
|
|
||||||||
|
Merck Sharp & Dohme Corp.
|
||||||||
|
National Cancer Centre Singapore
|
||||||||
|
National University Cancer Institute, Singapore
|
||||||||
|
Singapore Translational Cancer Consortium
|
リンク無しの社名は OpenBizGraph 未登録企業
§05
関連図
ドラッグで移動 · クリックで詳細へ
§07
ニュース
ニュースはありません。
§09
出典・更新
DOMAIN単独ドメイン：あり
UPDATED2026-11-07 08:26 · Model: gpt-oss-20b(99)